FTSE MIB
33.861,30 -20,20 (-0,06%) Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,17 -0,56 (-0,68%) Bitcoin EUR
61.204,86 +3.283,07 (+5,67%)
InspireMD, Inc. (NSPR)
Dopo ore:
| Chiusura precedente | 2,2100 |
| Aperto | 2,2001 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 2,0800 - 2,2001 |
| Intervallo di 52 settimane | 0,9600 - 3,8500 |
| Volume | |
| Media Volume | 37.096 |
| Capitalizzazione | 50,218M |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8200 |
| Prossima data utili | 14 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,50 |
GlobeNewswireInspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive CAS and TCAR procedures InspireMD advancing both CAS and TCAR stent delivery platforms along U.S. and E.U. regulatory pathways leveraging proven CGuard EPS stent system TEL AVIV, Israel and MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), dev
- GlobeNewswire
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager of North America & VP of Global Marketing, promoted to Chief Commercial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the
- GlobeNewswire
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas. Pr
